Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders

• Published in: Advances in biochemical psychopharmacology Vol. 37; p. 137
• Main Authors: Lloyd, K G, DeMontis, G, Broekkamp, C L, Thuret, F, Worms, P
• Format: Journal Article
• Language: English
• Published: United States 1983
• Subjects: Central Nervous System - metabolism; Epilepsy - metabolism; Humans; Huntington Disease - metabolism; Mental Disorders - metabolism; Nervous System Diseases - metabolism; Neurotransmitter Agents - physiology; Parkinson Disease - metabolism; Receptors, Cell Surface - metabolism; Receptors, GABA-A; Receptors, Glycine; Seizures - metabolism; Strychnine - metabolism
• ISSN: 0065-2229

From binding studies using 3H-GABA and 3H-strychnine in dissected human brain material, inhibitory amino acid neurotransmitter receptors have a widespread distribution in the human CNS. Generally GABA receptors are predominant in the forebrain and upper brainstem whereas glycine receptors are more localized in the lower brainstem and spinal cord. Some areas (eg. the substantia nigra) have appreciable quantities of both receptors. Although glycine receptors are altered in some pathological conditions (eg. in Parkinson's disease, in the substantia nigra) the neuropharmacology of the glycine system is still poorly understood. On the other hand the GABA system has been intensively studied. Dysfunction of GABA receptors occurs in various neurological states, as epilepsy, Parkinson's disease and Huntington's chorea. Furthermore GABA agonists are active in animal models for dyskinesia, epilepsy and depression, amongst others. Clinical studies with progabide confirm these findings in animal models, and suggest that low-medium affinity GABA agonists are more appropriate clinical agents than are high or very high affinity GABA agonists. From these and many other findings there appears to be a very large potential for creating new pharmacological agents for different neuropsychiatric disorders based on agonist activity at inhibitory amino-acid receptors. From the example of progabide these compounds can be made not only specific for the receptor involved, but also to have a lower incidence of neurotoxic effects than presently available drugs.